Treatment of endometriosis with gonadotropin releasing hormone agonist (buserelin)

R Sirimongkolkasem, Sirimongkolkasem R, A Rojanasakul, Rojanasakul A, Chailurkit Lo, L O Chailurkit
Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 1990 · vol. 73 Suppl 1 , pp. 37–41 · PMID:2112582 · W2400522814
Other OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-13 ⓘ

Intranasal buserelin effectively suppressed serum estradiol to menopausal levels, resulting in clinical improvement and regression of endometriotic lesions in patients with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The results of treatment of endometriosis with intranasal buserelin is convincing. The drug effectively suppresses serum estradiol to the menopausal level. Clinical improvement and regression of endometriotic lesions were observed during treatment. Thus, buserelin offers an alternative medical treatment of endometriosis. Further studies of the effects of GnRH agonist on bone mass are needed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Uterine Neoplasms Adult Adult Buserelin Buserelin Endometriosis Endometriosis Endometriosis Estradiol Estradiol Estradiol Female Female Gonadotropins, Pituitary Gonadotropins, Pituitary Gonadotropins, Pituitary Humans Humans

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-30T06:09:08.764285+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:21.741906+00:00
License: CC0 · commercial use OK